The Effects of Tiopronin on 3-Aminopropanal Level & Neurologic Outcome After Aneurysmal Subarachnoid Hemorrhage
Completed
Food and Drug Administration (FDA)
Phase 2
2010-04-01
The purpose of this phase II study is to further assess the safety of tiopronin in aneurysmal
subarachnoid hemorrhage(aSAH) patients in order to obtain preliminary data on the efficacy of
tiopronin versus placebo in reducing serum and cerebrospinal fluid (CSF) 3AP levels in this
patient population.
Funding Source - FDA Office of Orphan Products Development
The Effects of Tiopronin on 3-Aminopropanal Level & Neurologic Outcome After Aneurysmal Subarachnoid Hemorrhage
Completed
University of Florida
Phase 2
2010-04-01
The purpose of this phase II study is to further assess the safety of tiopronin in aneurysmal
subarachnoid hemorrhage(aSAH) patients in order to obtain preliminary data on the efficacy of
tiopronin versus placebo in reducing serum and cerebrospinal fluid (CSF) 3AP levels in this
patient population.
Funding Source - FDA Office of Orphan Products Development
The Effects of Tiopronin on 3-Aminopropanal Level & Neurologic Outcome After Aneurysmal Subarachnoid Hemorrhage
Completed
University of Washington
Phase 2
2010-04-01
The purpose of this phase II study is to further assess the safety of tiopronin in aneurysmal
subarachnoid hemorrhage(aSAH) patients in order to obtain preliminary data on the efficacy of
tiopronin versus placebo in reducing serum and cerebrospinal fluid (CSF) 3AP levels in this
patient population.
Funding Source - FDA Office of Orphan Products Development
The Effects of Tiopronin on 3-Aminopropanal Level & Neurologic Outcome After Aneurysmal Subarachnoid Hemorrhage
Completed
E. Sander Connolly
Phase 2
2010-04-01
The purpose of this phase II study is to further assess the safety of tiopronin in aneurysmal
subarachnoid hemorrhage(aSAH) patients in order to obtain preliminary data on the efficacy of
tiopronin versus placebo in reducing serum and cerebrospinal fluid (CSF) 3AP levels in this
patient population.
Funding Source - FDA Office of Orphan Products Development
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
